Matinas BioPharma Holdings, Inc.

AMEX

Market Cap.

4.73M

Avg. Volume

145.16K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. News

Matinas BioPharma Holdings, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
matinasbiopharma.com

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Matinas BioPharma Holdings, Inc. Earnings & Revenue

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Matinas BioPharma Holdings, Inc. Financials

Table Compare

Compare MTNB metrics with:

   

Earnings & Growth

MTNB

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

MTNB

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

MTNB

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

MTNB

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Matinas BioPharma Holdings, Inc. Income

Matinas BioPharma Holdings, Inc. Balance Sheet

Matinas BioPharma Holdings, Inc. Cash Flow

Matinas BioPharma Holdings, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Matinas BioPharma Holdings, Inc. Executives

NameRole
Mr. Jerome D. Jabbour J.D.Co-Founder, Chief Executive Officer & Chairman
Mr. Keith A. Kucinski CPA, M.B.A.Chief Financial Officer
Mr. Frank CalamusaExecutive Director and Head of Manufacturing & Supply Chain
NameRoleGenderDate of BirthPay
Mr. Jerome D. Jabbour J.D.Co-Founder, Chief Executive Officer & ChairmanMale1974598K
Mr. Keith A. Kucinski CPA, M.B.A.Chief Financial OfficerMale1970584.16K
Mr. Frank CalamusaExecutive Director and Head of Manufacturing & Supply ChainMale

--

Matinas BioPharma Holdings, Inc. Insider Trades

Date30 Apr
NameNEUGEBOREN EDWARD
RoleDirector
TransactionAcquired
TypeA-Award
Shares11600
Date30 Apr
NameSmith Robin L
RoleDirector
TransactionAcquired
TypeA-Award
Shares11600
Date30 Apr
NameD An Evelyn
RoleDirector
TransactionAcquired
TypeA-Award
Shares11600
Date30 Apr
NameJabbour Jerome D
RolePresident and CEO
TransactionAcquired
TypeA-Award
Shares70100
Date30 Apr
NameMurphy Keith
RoleDirector
TransactionAcquired
TypeA-Award
Shares11600
DateNameRoleTransactionTypeShares
30 AprNEUGEBOREN EDWARDDirectorAcquiredA-Award11600
30 AprSmith Robin LDirectorAcquiredA-Award11600
30 AprD An EvelynDirectorAcquiredA-Award11600
30 AprJabbour Jerome DPresident and CEOAcquiredA-Award70100
30 AprMurphy KeithDirectorAcquiredA-Award11600

Discover More

Streamlined Academy

Matinas BioPharma Holdings, Inc.

AMEX

Market Cap.

4.73M

Avg. Volume

145.16K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Matinas BioPharma Holdings, Inc. News

Matinas BioPharma Holdings, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Matinas BioPharma Holdings, Inc. Earnings & Revenue

Matinas BioPharma Holdings, Inc. Income

Matinas BioPharma Holdings, Inc. Balance Sheet

Matinas BioPharma Holdings, Inc. Cash Flow

Matinas BioPharma Holdings, Inc. Financials Over Time

Matinas BioPharma Holdings, Inc. Executives

NameRole
Mr. Jerome D. Jabbour J.D.Co-Founder, Chief Executive Officer & Chairman
Mr. Keith A. Kucinski CPA, M.B.A.Chief Financial Officer
Mr. Frank CalamusaExecutive Director and Head of Manufacturing & Supply Chain
NameRoleGenderDate of BirthPay
Mr. Jerome D. Jabbour J.D.Co-Founder, Chief Executive Officer & ChairmanMale1974598K
Mr. Keith A. Kucinski CPA, M.B.A.Chief Financial OfficerMale1970584.16K
Mr. Frank CalamusaExecutive Director and Head of Manufacturing & Supply ChainMale

--

Matinas BioPharma Holdings, Inc. Insider Trades

Date30 Apr
NameNEUGEBOREN EDWARD
RoleDirector
TransactionAcquired
TypeA-Award
Shares11600
Date30 Apr
NameSmith Robin L
RoleDirector
TransactionAcquired
TypeA-Award
Shares11600
Date30 Apr
NameD An Evelyn
RoleDirector
TransactionAcquired
TypeA-Award
Shares11600
Date30 Apr
NameJabbour Jerome D
RolePresident and CEO
TransactionAcquired
TypeA-Award
Shares70100
Date30 Apr
NameMurphy Keith
RoleDirector
TransactionAcquired
TypeA-Award
Shares11600
DateNameRoleTransactionTypeShares
30 AprNEUGEBOREN EDWARDDirectorAcquiredA-Award11600
30 AprSmith Robin LDirectorAcquiredA-Award11600
30 AprD An EvelynDirectorAcquiredA-Award11600
30 AprJabbour Jerome DPresident and CEOAcquiredA-Award70100
30 AprMurphy KeithDirectorAcquiredA-Award11600

Streamlined Academy

Website screenshot
HealthcareBiotechnology
matinasbiopharma.com

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Matinas BioPharma Holdings, Inc.

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Matinas BioPharma Holdings, Inc. Financials

Table Compare

Compare MTNB metrics with:

   

Earnings & Growth

MTNB

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

MTNB

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

MTNB

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

MTNB

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

The Secret to Analyzing Winning Stocks (Step-by-Step Examples Inside)